GILD vs STRO · P/E 18, rev $29.44B vs rev $62.0M
Gilead Sciences Inc (GILD) versus Sutro Biopharma (STRO) — a side-by-side from cached financials, not a winner call.
Gilead Sciences Inc (GILD) is a drug manufacturers - general company listed on US.
Sutro Biopharma (STRO) is a biotechnology company listed on NASDAQ.
Latest reported GILD revenue for 2025-12-31 was $29.44B. Net income was $8.51B. Revenue was up 2.4% from 2024-12-31 to 2025-12-31. GILD currently screens at market cap $160.15B and trailing P/E 17.5.
Latest reported STRO revenue for 2024-12-31 was $62.0M. Net income was -$227.5M. Revenue was down 59.6% from 2023-12-31 to 2024-12-31. STRO currently screens at market cap $470.8M.
GILD currently screens at market cap $160.15B and trailing P/E 17.5. STRO currently screens at market cap $470.8M.
Not investment advice. Open the GILD and STRO stock pages for the full models.
Not investment advice.